logo
This Incredibly Cheap Growth Stock Could Soar 44%, According to Wall Street Analysts

This Incredibly Cheap Growth Stock Could Soar 44%, According to Wall Street Analysts

Yahoo30-05-2025
Opera delivered outstanding results recently and its guidance points toward an improvement in its growth.
The stock is cheaply valued, and its earnings growth suggests it is on track to deliver solid gains to investors.
10 stocks we like better than Opera ›
Shares of Opera (NASDAQ: OPRA) have blown hot and cold on the market so far this year, as the company's strong quarterly results have been overshadowed by the broader stock market weakness; however, analysts are expecting shares of the Norway-based web browser maker to reverse the 8% drop they have witnessed so far in 2025 and head higher in the coming year.
Opera stock carries a 12-month price target of $25 as per the seven analysts covering the stock, with all of them having a buy rating. That points toward 44% gains from current levels. There is a good chance that Opera will be able to indeed deliver such solid gains and head higher thanks to its impressive growth and attractive valuation.
Let's look at the reasons why buying Opera stock right now could turn out to be a smart move.
Opera released its first-quarter results on April 28, and the company crushed Wall Street's expectations by a big margin. Its revenue shot up 40% year over year, while adjusted earnings increased by 35%. This marks a significant improvement from the year-ago period when the company reported a 17% jump in revenue and a flat bottom-line performance.
What's more, Opera has raised its full-year revenue growth guidance by three points to 20% to $575 million at the midpoint. The company, which is known for its web and mobile browsers, has been benefiting from the stronger monetization of its properties. Advertisers are now spending more money on the company's Opera Ads platform, which gives them multiple channels to reach its 293 million monthly active users (MAUs) across both mobile and desktop.
From programmatic advertising that uses real-time data to help advertisers buy and serve ads to premium display areas on its web browsers to push notifications and in-app notifications, Opera is trying to entice advertisers by offering multiple ways to display ads. The good part is that this strategy is paying off. Opera's ad revenue shot up an impressive 63% year over year in the previous quarter and accounted for two-thirds of its top line.
Another thing worth noting is that Opera's average revenue per user (ARPU) increased by an impressive 45% year over year in Q1, owing to the terrific growth of the advertising business. Looking ahead, there is a good chance that Opera will be able to win a bigger share of advertisers' wallets as it is integrating agentic artificial intelligence (AI) into its browsers that will perform tasks on users' behalf.
Opera's Browser Operator platform will allow users to shop online, book tickets, look for hotels, and complete other tasks on the web with the help of an AI agent that will take instructions from users before going about its job. This could help Opera strike more advertising deals through preferred partnerships and revenue-sharing models. For instance, the AI agent could direct the user toward a preferred travel booking website for booking tickets or hotels, and Opera could earn a commission out of the transaction.
All this explains why the company is now confident of delivering stronger growth in 2025. Even better, analysts are expecting Opera to maintain a healthy double-digit growth rate for the next couple of years as well.
Consensus estimates are projecting an 18% increase in Opera's earnings this year to $1.14 per share. That's expected to accelerate to 23% next year, which is not surprising considering the stellar improvement in the ARPU that the company clocked last quarter.
With Opera integrating new features, such as AI, into its browsers that could unlock more value for advertisers and encourage them to spend more on its platform, it won't be surprising to see the company's earnings growth accelerating beyond the next couple of years. That's why now would be a good time to buy this tech stock as it is trading at just 18.5 times earnings, a discount to the Nasdaq-100 index's earnings multiple of 31 (using the index as a proxy for tech stocks).
If the market decides to put a higher valuation on Opera because of its improving growth profile and it trades in line with the index's multiple after a year, its stock price could hit $35 (based on the projected earnings estimate for 2025). That would be nearly double the current levels, indicating that Opera has the potential to outpace analysts' one-year price target and skyrocket substantially going forward.
Before you buy stock in Opera, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Opera wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,985!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $853,108!*
Now, it's worth noting Stock Advisor's total average return is 978% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of May 19, 2025
Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
This Incredibly Cheap Growth Stock Could Soar 44%, According to Wall Street Analysts was originally published by The Motley Fool
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Flex LNG - Launch of Share Buyback Program
Flex LNG - Launch of Share Buyback Program

Yahoo

time14 minutes ago

  • Yahoo

Flex LNG - Launch of Share Buyback Program

HAMILTON, Bermuda, Aug. 20, 2025 /PRNewswire/ -- The Board of Directors of Flex LNG Ltd. ("Flex LNG" or the "Company") authorized a share buyback program that allows the Company to repurchase up to $15 million of its outstanding shares. In furtherance of the program, the Company announces today that it has put in place an agreement with DNB Markets, Inc. and DNB Carnegie, a part of DNB Bank ASA, for the repurchase of the Company's shares in open market transactions on the Oslo Stock Exchange ("OSE") and the New York Stock Exchange ("NYSE"). Repurchases on the OSE will be completed in accordance with the Market Abuse Regulation (EU) No 596/2014 and Commission Delegated Regulation (EU) 2016/1052. Repurchases on the NYSE will be made in accordance with U.S. securities laws and regulations, including compliance with the safe harbor provided by Rule 10b-18 promulgated by the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended. The share buyback program will commence on August 20, 2025 and continue through November 27, 2025. The Company may repurchase up to $15 million of its shares, subject also to a maximum limit of 900,000 shares. The shares purchased will be held as treasury shares. The actual timing, number and value of shares repurchased under the repurchase program will depend on several factors, including the manner, timing, and volume restrictions specified in Rule 10b-18, price, general business and market conditions, and alternative investment opportunities. The Company reserves the right to make subsequent changes to the above terms for the program, including shortening, extending and/or replacing the program. The amount utilized for the share buyback program will be treated independently from future dividend consideration, which remains at the discretion of the Board of Directors in accordance with the Company's dividend policy. For further information, please contact: Mr. Knut Traaholt, Chief Financial Officer of Flex LNG Management ASTelephone: +47 23 11 40 00Email: ir@ This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act and article 5 of the European Market Abuse Regulation. Forward-Looking Statements Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words "believe," "expect," "forecast," "anticipate," "aim," "commit," "estimate," "intend," "plan," "possible," "potential," "pending," "target," "project," "likely," "may," "will," "would," "should," "could" and similar expressions identify forward-looking statements. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management's examination of historical operating trends, data contained in the Company's records and other data available from third parties. Although management believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond the Company's control, there can be no assurance that the Company will achieve or accomplish these expectations, beliefs or projections. As such, these forward-looking statements are not guarantees of the Company's future performance, and actual results and future developments may vary materially from those projected in the forward-looking statements. The Company undertakes no obligation, and specifically declines any obligation, except as required by applicable law or regulation, to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for the Company to predict all of these factors. Further, the Company cannot assess the effect of each such factor on its business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statement. In addition to these important factors, other important factors that, in the Company's view, could cause actual results to differ materially from those discussed in the forward-looking statements include: unforeseen liabilities, future capital expenditures, the strength of world economies and currencies, inflationary pressures and central bank policies intended to combat overall inflation and rising interest rates and foreign exchange rates, general market conditions, including fluctuations in charter rates and vessel values, changes in demand in the LNG tanker market, the impact of public health threats, changes in the Company's operating expenses, including bunker prices, drydocking and insurance costs, the fuel efficiency of the Company's vessels, the market for the Company's vessels, availability of financing and refinancing, ability to comply with covenants in such financing arrangements, failure of counterparties to fully perform their contracts with the Company, changes in governmental rules and regulations or actions taken by regulatory authorities, including those that may limit the commercial useful lives of LNG tankers, customers' increasing emphasis on environmental and safety concerns, potential liability from pending or future litigation, global and regional economic and political conditions or developments, armed conflicts, including the war between Russia and Ukraine, and possible cessation of such war in Ukraine, the conflict between Israel and Hamas and related conflicts in the Middle East, the Houthi attack in the Red Sea and Gulf of Aden, threats by Iran to close the Strait of Hormuz, trade wars, tariffs, embargoes and strikes, the impact of restrictions on trade, including the imposition of new tariffs, port fees and other import restrictions by the United States on its trading partners and the imposition of retaliatory tariffs by China and the European Union on the United States, business disruptions, including supply chain disruption and congestion, due to natural or other disasters or otherwise, potential physical disruption of shipping routes due to accidents, climate-related incidents, or political events, potential cybersecurity or other privacy threats and data security breaches, vessel breakdowns and instances of offhire, and other factors, including those that may be described from time to time in the reports and other documents that the Company files with or furnishes to the U.S. Securities and Exchange Commission ("Other Reports"). For a more complete discussion of certain of these and other risks and uncertainties associated with the Company, please refer to the Other Reports. This information was brought to you by Cision View original content: SOURCE Flex LNG

Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update

Yahoo

time14 minutes ago

  • Yahoo

Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update

Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic 'off-the-shelf' T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its second quarter 2025 results today. Webcast scheduled for 20 August 2025, at 09:00 (CET). Link to webcast here. Second Quarter 2025 Business Update Highlights On track toward IND/CTA submission in 2H 2025 and first-in-human trial initiation in 1H 2026. Broadened regulatory engagement: following positive FDA pre-IND feedback (Q2 2024), submitted a scientific advice briefing package to the UK MHRA in July 2025 for ZI-MA4-1. Initiated GMP manufacturing of clinical material in July 2025, a major step in clinical readiness; scalable platform developed with Catalent can deliver hundreds of doses from a single batch. Strong support from leading clinical experts and sites; refined trial design and moving to operational readiness ahead of IND/CTA submission Financial highlights Total operating expenses amounted to MNOK 38.4 in Q2 2025, and MNOK 67.8 YTD. Total loss was MNOK 37.5 for the period and MNOK 66.0 YTD. Net negative cash flow from operations was MNOK 59.4 in Q2 2025, and net decrease in cash and cash equivalents, excluding currency effects, was MNOK 59.0 during Q2 2025. Cash and cash equivalents amounted to MNOK 76.0 as per 30 June 2025. The current cash is expected to give a financial runway into Q2 2026, slightly shortened from the previously guided 'through Q2 2026' due to some one-off cost elements mainly related to investment in the successful development of the TCR-NK manufacturing process. The expected financial runway reflects that the cash burn rate is forecasted to come down significantly from the Q2 2025 level. On 27 May 2025, Zelluna ASA issued 227,096 new shares, each with a subscription price of NOK 26, to settle an amount of EUR 500,000 of an already triggered option exercise fee towards Inven2. The quarterly report and presentation will be published at 07:00 CET on 20 August 2025, and will be publicly available on the Zelluna website. The Company will conduct a webcast at 09:00 CET the same day, and questions can be submitted throughout the event. The webcast will be archived for replay following the conference call. Link to webcast here. For further information, please see or contact: Namir Hassan, CEO, Zelluna ASAEmail: +44 7720 687608 Hans Vassgård Eid, CFO, Zelluna ASAEmail: +47 482 48632 About Zelluna ASA Zelluna's mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global scale. The Company aims to do this by combining the most powerful elements of the immune system through pioneering the development of 'off-the-shelf' T-cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). The TCR-NK platform offers a unique mechanism of action with broad cancer detection capability to overcome the diversity of tumours and will be used 'off-the-shelf' to overcome scaling limitations of current cell therapies. The lead program is a world's first MAGE-A4 targeting 'off-the-shelf' TCR-NK for the treatment of various solid cancers; a pipeline of earlier products follows. The Company is led by a management team of biotech entrepreneurs with deep experience in discovery through clinical development of TCR and cell-based therapies including marketed products. For more information, please visit This stock exchange announcement was published by Joachim Midttun, Financial Manager at Zelluna ASA, on 20 August 2025 at 07:00 CET. Attachments Zelluna-ASA-Q225-Report Zelluna-ASA-Q225-Presentation

Dr. Lal PathLabs becomes first in India to adopt AI-based module for cancer lymph node metastasis detection
Dr. Lal PathLabs becomes first in India to adopt AI-based module for cancer lymph node metastasis detection

Business Upturn

time17 minutes ago

  • Business Upturn

Dr. Lal PathLabs becomes first in India to adopt AI-based module for cancer lymph node metastasis detection

Dr. Lal PathLabs has taken a groundbreaking step in advancing cancer diagnostics in India by becoming the first laboratory in the country to introduce a deep learning-based AI module for the detection of lymph node metastasis, including micrometastasis. This innovation, developed in collaboration with Singapore-based healthtech company Qritive, was recently showcased at USCAP 2025, one of the most prestigious pathology conferences in the world. The accurate detection of cancer spread to lymph nodes is a critical factor in determining the stage and treatment strategy for patients. Missing these signs of cancer progression can allow the disease to advance, increasing the chances of it spreading to distant organs and reducing survival rates. The ability to identify even occult metastases in patients with early-stage cancer has the potential to significantly influence treatment plans and improve outcomes. Traditionally, detecting micrometastases—small clusters of cancer cells hidden in lymph nodes—has been a time-consuming and complex process, often requiring advanced testing. The new AI system, called QiAI Lymph Node Dx, addresses this challenge by using deep learning to analyze digital slides and identify cancer cells with exceptional precision. This integration of AI into diagnostic practice ensures that cancer detection becomes faster, more reliable, and highly accurate. What makes this development especially impactful is its ability to pick up even single cancer cells, which were later validated through immunohistochemistry testing. The AI model has been tested across various cancer types, including breast, colon, stomach, and esophageal cancers, consistently delivering highly accurate results. Breast cancer, which accounts for nearly 28% of cancer cases among women in India, particularly stands to benefit from this breakthrough, highlighting the clinical relevance of the technology. By achieving complete sensitivity and negative predictive value—meaning no metastatic cases went undetected—the AI system has proven to be a robust screening tool. Its tumor-agnostic design allows it to function effectively across different cancer types, making it a versatile solution for oncologists and pathologists alike. As cancer incidence continues to rise in India, the integration of advanced AI-powered diagnostic tools such as QiAI Lymph Node Dx is set to transform the landscape of cancer care. By enabling earlier and more accurate diagnoses, this technology not only improves the efficiency of medical practice but also ensures better treatment decisions, offering renewed hope to patients battling cancer. Ahmedabad Plane Crash

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store